Cargando…

New emerging SARS-CoV-2 variants and antiviral agents

Detalles Bibliográficos
Autores principales:	Vitiello, A., Zovi, A., Rezza, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292910/ https://www.ncbi.nlm.nih.gov/pubmed/37390619 http://dx.doi.org/10.1016/j.drup.2023.100986

Ejemplares similares

How Antivirals Might be Linked to the Emergence of New Variants of SARS-CoV-2
por: Mehdizadeh, Ali Reza, et al.
Publicado: (2021)

Association between microbiota and immune response to Sars-CoV-2 infection
por: Vitiello, A., et al.
Publicado: (2023)

Special Issue “Advances in Antiviral Agents against SARS-CoV-2 and Its Variants”
por: Esposito, Francesca, et al.
Publicado: (2023)

The direct correlation between microbiota and SARS-CoV-2 infectious disease
por: Vitiello, Antonio, et al.
Publicado: (2023)

The impact of SARS-CoV-2 infection in patients with cystic fibrosis undergoing CFTR channel modulators treatment: a literature review
por: Vitiello, Antonio, et al.
Publicado: (2023)

Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents
por: Ayaz, Sameer, et al.
Publicado: (2020)

COVID-19 Vaccination Strategies and Their Adaptation to the Emergence of SARS-CoV-2 Variants
por: Stefanelli, Paola, et al.
Publicado: (2022)

Pharmacological Agents with Antiviral Activity against Monkeypox Infection
por: Zovi, Andrea, et al.
Publicado: (2022)

The emergence, dynamics and significance of SARS-CoV-2 variants
por: COLSON, Philippe, et al.
Publicado: (2022)

Emerging SARS-CoV-2 variants: shooting the messenger
por: The Lancet Infectious Diseases
Publicado: (2022)

Implications of the Emerging SARS-CoV-2 Variant: Caution is the Key
por: Al Awaidy, Salah T., et al.
Publicado: (2021)

The Emergence of Hybrid Variants of SARS-CoV-2: Towards Hybrid Immunity
por: Chavda, Vivek P., et al.
Publicado: (2023)

New Variants in SARS-CoV-2: What are we Learning from the Omicron Variant?
por: Galán, Juan Carlos, et al.
Publicado: (2022)

SARS-CoV-2 caused a surge in antibiotic consumption causing a silent pandemic inside the pandemic. A retrospective analysis of Italian data in the first half of 2022
por: Ferrara, F., et al.
Publicado: (2023)

Potential Immunoregulatory and Antiviral/SARS-CoV-2 Activities of Nitric Oxide
por: Stefano, George B., et al.
Publicado: (2020)

Editorial: Factors Driving New Variants of SARS-CoV-2, Immune Escape, and Resistance to Antiviral Treatments as the End of the COVID-19 Pandemic is Declared
por: Parums, Dinah V.
Publicado: (2023)

Emergence of a new SARS-CoV-2 variant in the UK
por: Tang, Julian W, et al.
Publicado: (2021)

SARS-CoV-2: Evolution and Emergence of New Viral Variants
por: Flores-Vega, Verónica Roxana, et al.
Publicado: (2022)

SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
por: Elshabrawy, Hatem A.
Publicado: (2020)

SARS-CoV-2 variants of concern: the knowns and unknowns
por: Lessells, Richard J.
Publicado: (2021)

Evolution and Clinical Trend of SARS-CoV-2 Variants
por: Lorente-González, Miguel, et al.
Publicado: (2022)

Supporting the Aspecific Physiological Defenses of Upper Airways against Emerging SARS-CoV-2 Variants
por: Cegolon, Luca, et al.
Publicado: (2023)

A new enemy is emerging in the fight against the SARS-CoV-2 pandemic
por: Rodeghiero, Francesco, et al.
Publicado: (2021)

SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines
por: Singh, Desh Deepak, et al.
Publicado: (2021)

Emergence of SARS-CoV-2 New Variants and Their Clinical Significance
por: Singh, Hitesh, et al.
Publicado: (2022)

The Emergence of the Omicron (B.1.1.529) SARS-CoV-2 Variant: What is the Impact on the Continued Pandemic?
por: Al-Tawfiq, Jaffar A., et al.
Publicado: (2022)

Evolution of SARS-CoV-2 mutational variants: Hysteria or hope for the future?
por: Esmail, A, et al.
Publicado: (2021)

The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?
por: Jans, David A., et al.
Publicado: (2021)

Knowledge Gaps for Prophylactic Use of Antithrombotic Agents in Patients with COVID-19: Insights into New SARS-CoV-2 Variants, Vaccination Status, and Emerging Oral Antivirals
por: Talasaz, Azita H., et al.
Publicado: (2022)

Initiation of Antiviral Treatment in SARS‐CoV2: Modeling Viral Dynamics and Drug Properties
por: Rosenbloom, Daniel Scholes, et al.
Publicado: (2020)

The evolution of SARS-CoV-2 variants and their clinical and healthcare implications()
por: Eiros, J.M., et al.
Publicado: (2022)

Approaching Challenges Posed by SARS-CoV-2 Genetic Variants
por: de la Fuente, José
Publicado: (2022)

Discovery of adapalene and dihydrotachysterol as antiviral agents for the Omicron variant of SARS-CoV-2 through computational drug repurposing
por: Fidan, Ozkan, et al.
Publicado: (2022)

Possible effect of the “original antigenic sin” in vaccination against new variants of SARS-CoV-2()
por: Reina, J.
Publicado: (2022)

The emerging SARS-CoV-2 variants of concern
por: Sanyaolu, Adekunle, et al.
Publicado: (2021)

Emerging dominant SARS-CoV-2 variants
por: Chen, Jiahui, et al.
Publicado: (2022)

Characterization of a new SARS-CoV-2 variant that emerged in Brazil
por: Imai, Masaki, et al.
Publicado: (2021)

Emerging mutation patterns in SARS-CoV-2 variants
por: Ostrov, David A., et al.
Publicado: (2022)

Antibacterial and antiviral high-performance nanosystems to mitigate new SARS-CoV-2 variants of concern
por: Tiwari, Shivani, et al.
Publicado: (2022)

Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir
por: Parums, Dinah V.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i1c9fff1nusrus61317r2vfulo